The trial will enroll participants — kidney and liver transplant recipients — who did not generate a detectable antibody response after two to four doses of Pfizer or Moderna’s mRNA vaccine, according to a Jan. 31 news release. Researchers will analyze whether temporarily reducing immunosuppressive medication taken during the days before and after an additional dose safely allows for stronger antibody responses to vaccination.
“Eliciting a protective immune response to COVID-19 vaccines in some organ transplant recipients continues to be a challenge,” said Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases. “We are concerned about protecting everyone from COVID-19 and therefore continue to develop and test new approaches to make vaccination effective for all organ transplant recipients.”
Researchers plan to enroll 400 adults who received a kidney or liver transplant at least one year before enrollment.
To learn more, click here.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
